To assess the effect of insulin delivery and glucose monitoring technologies on quality of life in relation with glucose control in adults with type 1 diabetes (T1D).
Methods
This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics.
Results
Individuals in the CSII group reported higher treatment-related satisfaction (p = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (p > 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (p = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (p = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (p = 0.0003).
Conclusions
Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect.
{"title":"Impact of technologies on quality of life in relation to glucose control in patients with type 1 diabetes","authors":"Silvia Irina Briganti , Oreste Lanza , Valerio Renzelli , Giuseppe Campagna , Daria Maggi , Massimiliano Caprio , Silvia Manfrini , Rocky Strollo","doi":"10.1016/j.jdiacomp.2025.109215","DOIUrl":"10.1016/j.jdiacomp.2025.109215","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the effect of insulin delivery and glucose monitoring technologies on quality of life in relation with glucose control in adults with type 1 diabetes (T1D).</div></div><div><h3>Methods</h3><div>This cross-sectional study included 69 adults with T1D (mean age 39.3 ± 12.1 years; 44.9 % females): 36 on multiple daily insulin injections (MDI) and 33 on continuous subcutaneous insulin infusion (CSII). Patient-reported outcomes were assessed using the Diabetes Treatment Satisfaction Questionnaire (DTSQ), Diabetes-Specific Quality of Life Scale (DSQOLS), and SF-36. Glucose control was evaluated using HbA1c and CGM metrics.</div></div><div><h3>Results</h3><div>Individuals in the CSII group reported higher treatment-related satisfaction (<em>p</em> = 0.004), and better disease acceptance (p = 0.004) compared with individuals on MDI, despite similar age, sex or disease duration (<em>p</em> > 0.34). Time in range (TIR) resulted higher in the CSII group than in the MDI group (<em>p</em> = 0.02), while time below range (TBR) resulted higher in the MDI group compared to CSII (<em>p</em> = 0.03). Individuals reporting high satisfaction scores demonstrated better glucose control metrics compared to those with lower satisfaction levels. The association between satisfaction and TIR was relevant, even after adjusting for treatment modality (<em>p</em> = 0.0003).</div></div><div><h3>Conclusions</h3><div>Technology may improve quality of life over MDI treatment. Improvement in glucose control may partially account for this effect.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109215"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145518206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-24DOI: 10.1016/j.jdiacomp.2025.109231
Mahmoud Ibrahim , Ebtesam M. Ba-Essa , Asma Ahmed , David G. Armstrong , Mario Barmaki , Avivit Cahn , Kevin Cassar , Omer Hamtzany , José Luis Lázaro Martínez , Helard Manrique , Omar Mobarak , Ashu Rastogi , Manfredi Rizzo , Shehla Shaikh , Guillermo E. Umpierrez
Diabetes-related foot disease is a significant source of morbidity and mortality among people with diabetes, affecting approximately 1.8 % of the global population and leading to many hospital admissions and non-traumatic amputations. Structured multidisciplinary care for the management of diabetes-related foot disease has been shown to reduce complication rates. The role of primary care providers is crucial in the education, recognition, management, and referral of people with diabetes-related foot disease. This evidence-based review article combines expert opinion with research-based consensus to offer comprehensive yet actionable guidance for primary care providers. It discusses the different domains of care for diabetes-related foot disease, including prevention, cardiometabolic biomarkers, education, risk stratification, complication detection, disease staging, treatment options, and management considerations for different geographic populations.
{"title":"Current primary care approaches to diabetic foot prevention and treatment","authors":"Mahmoud Ibrahim , Ebtesam M. Ba-Essa , Asma Ahmed , David G. Armstrong , Mario Barmaki , Avivit Cahn , Kevin Cassar , Omer Hamtzany , José Luis Lázaro Martínez , Helard Manrique , Omar Mobarak , Ashu Rastogi , Manfredi Rizzo , Shehla Shaikh , Guillermo E. Umpierrez","doi":"10.1016/j.jdiacomp.2025.109231","DOIUrl":"10.1016/j.jdiacomp.2025.109231","url":null,"abstract":"<div><div>Diabetes-related foot disease is a significant source of morbidity and mortality among people with diabetes, affecting approximately 1.8 % of the global population and leading to many hospital admissions and non-traumatic amputations. Structured multidisciplinary care for the management of diabetes-related foot disease has been shown to reduce complication rates. The role of primary care providers is crucial in the education, recognition, management, and referral of people with diabetes-related foot disease. This evidence-based review article combines expert opinion with research-based consensus to offer comprehensive yet actionable guidance for primary care providers. It discusses the different domains of care for diabetes-related foot disease, including prevention, cardiometabolic biomarkers, education, risk stratification, complication detection, disease staging, treatment options, and management considerations for different geographic populations.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109231"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-25DOI: 10.1016/j.jdiacomp.2025.109236
Qi Fan , Guoqiang Qin , Bingyu Du , Mengfan Kan , Mengyuan Li , Qiu Li , Zhongwen Zhang
Aim
To evaluate the clinical efficacy and explore the potential mechanisms of novel mineralocorticoid receptor antagonists (MRAs) in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM).
Methods
Randomized controlled trials (RCTs), including relevant subgroup analyses, of steroidal MRAs (eplerenone, canrenone) and non-steroidal MRAs (finerenone, esaxerenone) in T2DM patients were identified through systematic searches of English and Chinese databases. Meta-analysis was performed to assess clinical outcomes, and network pharmacology was used to explore underlying molecular mechanisms.
Result
18 RCTs (including relevant subgroup analyses) involving 30,103 participants were included. MRAs significantly reduced MACE risk (OR = 0.81, 95 % CI: 0.75–0.86; P < 0.00001). MRAs also significantly decreased cardiovascular mortality (OR = 0.86, 95 % CI: 0.77–0.97; P = 0.01) and hospitalization for heart failure (OR = 0.77, 95 % CI: 0.68–0.87; P < 0.0001). Network pharmacology identified that steroidal MRAs mainly act via IL-17 and relaxin signaling pathways, targeting MAPK10, GSK3B, PTGS2, NOS2, and MMP1. Non-steroidal MRAs primarily modulate Ras and relaxin pathways, involving targets such as EGFR and PIK3C.
Conclusions
This study provides high-certainty evidence supporting MRAs in reducing MACE and heart failure hospitalization, and moderate-certainty evidence for benefits on cardiovascular mortality. Cardioprotective effects may involve Ras, IL-17, and relaxin signaling.
目的评价新型矿皮质激素受体拮抗剂（MRAs）降低2型糖尿病（T2DM）患者主要不良心血管事件（MACE）风险的临床疗效并探讨其潜在机制。方法通过系统检索中英文数据库，对2型糖尿病患者的甾体MRAs （eplerenone、canrenone）和非甾体MRAs （finerenone、esaxerenone）进行随机对照试验（rct），并进行亚组分析。meta分析用于评估临床结果，网络药理学用于探索潜在的分子机制。结果共纳入18项随机对照试验（含相关亚组分析），共纳入30103名受试者。MRAs显著降低MACE风险（OR = 0.81, 95% CI: 0.75-0.86; P < 0.00001）。MRAs还显著降低心血管死亡率（OR = 0.86, 95% CI: 0.77 - 0.97; P = 0.01）和心力衰竭住院率（OR = 0.77, 95% CI: 0.68-0.87; P < 0.0001）。网络药理学发现甾体MRAs主要通过IL-17和松弛素信号通路起作用，靶向MAPK10、GSK3B、PTGS2、NOS2和MMP1。非甾体MRAs主要调节Ras和松弛素通路，涉及EGFR和PIK3C等靶点。结论：本研究提供了高确定性证据支持MRAs降低MACE和心力衰竭住院率，中等确定性证据支持MRAs对心血管死亡率的益处。心脏保护作用可能涉及Ras、IL-17和松弛素信号。
{"title":"Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients","authors":"Qi Fan , Guoqiang Qin , Bingyu Du , Mengfan Kan , Mengyuan Li , Qiu Li , Zhongwen Zhang","doi":"10.1016/j.jdiacomp.2025.109236","DOIUrl":"10.1016/j.jdiacomp.2025.109236","url":null,"abstract":"<div><h3>Aim</h3><div>To evaluate the clinical efficacy and explore the potential mechanisms of novel mineralocorticoid receptor antagonists (MRAs) in reducing the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>Randomized controlled trials (RCTs), including relevant subgroup analyses, of steroidal MRAs (eplerenone, canrenone) and non-steroidal MRAs (finerenone, esaxerenone) in T2DM patients were identified through systematic searches of English and Chinese databases. Meta-analysis was performed to assess clinical outcomes, and network pharmacology was used to explore underlying molecular mechanisms.</div></div><div><h3>Result</h3><div>18 RCTs (including relevant subgroup analyses) involving 30,103 participants were included. MRAs significantly reduced MACE risk (OR = 0.81, 95 % CI: 0.75–0.86; <em>P</em> < 0.00001). MRAs also significantly decreased cardiovascular mortality (OR = 0.86, 95 % CI: 0.77–0.97; <em>P</em> = 0.01) and hospitalization for heart failure (OR = 0.77, 95 % CI: 0.68–0.87; <em>P</em> < 0.0001). Network pharmacology identified that steroidal MRAs mainly act via IL-17 and relaxin signaling pathways, targeting MAPK10, GSK3B, PTGS2, NOS2, and MMP1. Non-steroidal MRAs primarily modulate Ras and relaxin pathways, involving targets such as EGFR and PIK3C.</div></div><div><h3>Conclusions</h3><div>This study provides high-certainty evidence supporting MRAs in reducing MACE and heart failure hospitalization, and moderate-certainty evidence for benefits on cardiovascular mortality. Cardioprotective effects may involve Ras, IL-17, and relaxin signaling.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109236"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145615454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MicroRNAs (miRNAs) are critical regulators of gene expression and have emerged as promising biomarkers and therapeutic targets in type 2 diabetes (T2D). Among them, the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) plays key roles in insulin sensitivity, pancreatic β-cell survival, and inflammation. Dysregulation of miR-200a/b and miR-200c has been linked to insulin resistance and β-cell apoptosis, although findings are context dependent, with miR-200c showing both protective and deleterious effects. Therapeutic approaches include the use of antagomiRs to inhibit miR-200a/b (to improve insulin sensitivity) and miR-200c mimics at physiological/ moderate level (to enhance β-cell resilience under oxidative stress). Advances in nanoparticle delivery systems (liposomes, micelles, dendrimers) and chemical modifications such as 2′-O-methyl, 2′-O-methoxyethyl, and locked nucleic acids have improved stability and efficacy, though barriers remain in achieving tissue specificity and minimizing immune activation. In addition to therapy, miR-200 family members are attractive non-invasive biomarkers, with recent studies reporting encouraging sensitivity and specificity for early T2D detection and monitoring of disease progression. However, major challenges persist, including delivery barriers, long-term safety concerns, and limited validation in large, multi-ethnic human cohorts. This review synthesizes current evidence on the dual potential therapeutic strategies of miR-200 inhibition and mimicry, evaluates their biomarker utility, and highlights future directions needed to overcome translational gaps. By addressing these limitations, miR-200-based strategies hold potential to advance toward clinical application in T2D.
MicroRNAs （miRNAs）是基因表达的关键调控因子，已成为2型糖尿病（T2D）有前景的生物标志物和治疗靶点。其中，miR-200家族（miR-200a、miR-200b、miR-200c、miR-141和miR-429）在胰岛素敏感性、胰腺β细胞存活和炎症中起关键作用。miR-200a/b和miR-200c的失调与胰岛素抵抗和β细胞凋亡有关，尽管研究结果依赖于环境，miR-200c显示出保护和有害作用。治疗方法包括使用拮抗剂在生理/中等水平抑制miR-200a/b（改善胰岛素敏感性）和miR-200c模拟物（增强氧化应激下β细胞的恢复能力）。纳米颗粒递送系统（脂质体、胶束、树突大分子）和化学修饰（如2'- o -甲基、2'- o -甲氧基乙基和锁定核酸）的进步提高了稳定性和有效性，尽管在实现组织特异性和最小化免疫激活方面仍然存在障碍。除了治疗之外，miR-200家族成员是有吸引力的非侵入性生物标志物，最近的研究报告了早期T2D检测和疾病进展监测的令人鼓舞的敏感性和特异性。然而，主要的挑战仍然存在，包括递送障碍、长期安全问题以及在大型多种族人群中的有限验证。这篇综述综合了目前关于miR-200抑制和模仿的双重潜在治疗策略的证据，评估了它们的生物标志物效用，并强调了克服翻译空白所需的未来方向。通过解决这些局限性，基于mir -200的策略有可能在T2D的临床应用中取得进展。
{"title":"The miR-200 family in type 2 diabetes: therapeutic and biomarker perspectives","authors":"Toluwalope Esther Ajonijebu , Sithandiwe Eunice Mazibuko-Mbeje","doi":"10.1016/j.jdiacomp.2025.109211","DOIUrl":"10.1016/j.jdiacomp.2025.109211","url":null,"abstract":"<div><div>MicroRNAs (miRNAs) are critical regulators of gene expression and have emerged as promising biomarkers and therapeutic targets in type 2 diabetes (T2D). Among them, the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, and miR-429) plays key roles in insulin sensitivity, pancreatic β-cell survival, and inflammation. Dysregulation of miR-200a/b and miR-200c has been linked to insulin resistance and β-cell apoptosis, although findings are context dependent, with miR-200c showing both protective and deleterious effects. Therapeutic approaches include the use of antagomiRs to inhibit miR-200a/b (to improve insulin sensitivity) and miR-200c mimics at physiological/ moderate level (to enhance β-cell resilience under oxidative stress). Advances in nanoparticle delivery systems (liposomes, micelles, dendrimers) and chemical modifications such as 2′-<em>O</em>-methyl, 2′-O-methoxyethyl, and locked nucleic acids have improved stability and efficacy, though barriers remain in achieving tissue specificity and minimizing immune activation. In addition to therapy, miR-200 family members are attractive non-invasive biomarkers, with recent studies reporting encouraging sensitivity and specificity for early T2D detection and monitoring of disease progression. However, major challenges persist, including delivery barriers, long-term safety concerns, and limited validation in large, multi-ethnic human cohorts. This review synthesizes current evidence on the dual potential therapeutic strategies of miR-200 inhibition and mimicry, evaluates their biomarker utility, and highlights future directions needed to overcome translational gaps. By addressing these limitations, miR-200-based strategies hold potential to advance toward clinical application in T2D.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109211"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-10-20DOI: 10.1016/j.jdiacomp.2025.109202
Salwa Dilfari Pohan , Rani Sauriasari , Baitha Palanggatan Maggadani , Taufiq Indra Rukmana , Farah Mahdiyah , Fathia Yusrina , Sri Hayati , Richard Johari James , Mohd Salleh Rofiee , Teh Lay Kek , Mohd Zaki Salleh
Objectives
This study investigated the relationship between serum metabolomic profiles and diabetic kidney disease (DKD) risk in patients with type 2 diabetes mellitus (T2DM) stratified into three KDIGO-defined risk categories.
Methods
Serum samples from 48 patients were analyzed using untargeted liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). Participants were classified into low (n = 16), moderate (n = 16), and high (n = 16) DKD risk groups according to KDIGO guidelines. Differential metabolites were identified based on p-value, log fold change, and variable importance in projection (VIP), and subsequently subjected to pathway enrichment analysis.
Results
Comparative analysis revealed five differential metabolites between low- and moderate-risk groups, three between moderate- and high-risk groups, and three between low- and high-risk groups. Notably, sphinganine, arachidonic acid, and ornithine were progressively downregulated, whereas AFMK, L-arginine, lactosylceramide (LacCer), and lysophosphatidylcholine (lysoPC) were upregulated with increasing DKD risk. These metabolites mapped to disturbed pathways, including arginine and proline metabolism, sphingolipid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism, and tryptophan metabolism.
Conclusion
This study highlights progressive alterations in amino acid, lipid, and inflammatory pathways across DKD risk categories, suggesting that these stage-specific metabolomic signatures may serve as putative biomarkers for detection and monitoring of DKD progression in T2DM.
{"title":"Serum analysis of type 2 diabetes mellitus patients with low, moderate, and high risk of diabetic kidney disease using LC-MS metabolomics approach","authors":"Salwa Dilfari Pohan , Rani Sauriasari , Baitha Palanggatan Maggadani , Taufiq Indra Rukmana , Farah Mahdiyah , Fathia Yusrina , Sri Hayati , Richard Johari James , Mohd Salleh Rofiee , Teh Lay Kek , Mohd Zaki Salleh","doi":"10.1016/j.jdiacomp.2025.109202","DOIUrl":"10.1016/j.jdiacomp.2025.109202","url":null,"abstract":"<div><h3>Objectives</h3><div>This study investigated the relationship between serum metabolomic profiles and diabetic kidney disease (DKD) risk in patients with type 2 diabetes mellitus (T2DM) stratified into three KDIGO-defined risk categories.</div></div><div><h3>Methods</h3><div>Serum samples from 48 patients were analyzed using untargeted liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF/MS). Participants were classified into low (<em>n</em> = 16), moderate (n = 16), and high (n = 16) DKD risk groups according to KDIGO guidelines. Differential metabolites were identified based on <em>p</em>-value, log fold change, and variable importance in projection (VIP), and subsequently subjected to pathway enrichment analysis.</div></div><div><h3>Results</h3><div>Comparative analysis revealed five differential metabolites between low- and moderate-risk groups, three between moderate- and high-risk groups, and three between low- and high-risk groups. Notably, sphinganine, arachidonic acid, and ornithine were progressively downregulated, whereas AFMK, L-arginine, lactosylceramide (LacCer), and lysophosphatidylcholine (lysoPC) were upregulated with increasing DKD risk. These metabolites mapped to disturbed pathways, including arginine and proline metabolism, sphingolipid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism, and tryptophan metabolism.</div></div><div><h3>Conclusion</h3><div>This study highlights progressive alterations in amino acid, lipid, and inflammatory pathways across DKD risk categories, suggesting that these stage-specific metabolomic signatures may serve as putative biomarkers for detection and monitoring of DKD progression in T2DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109202"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145569414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01Epub Date: 2025-11-21DOI: 10.1016/j.jdiacomp.2025.109228
Jared Rosenberg , Allison Williams , Anny Gano , Molly M. Deak , Gabriel Q. Shaibi , Joon Young Kim
Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the two incretin hormones, play an important pathophysiological role in glucose homeostasis with insulinotropic effects on the pancreatic β-cells. While two previous studies in youth have examined the effects of a lifestyle intervention on incretin concentrations, neither study focused on improvements in glycemic status or oral glucose tolerance test (OGTT)-derived biomarkers. Therefore, we aimed to examine changes in the incretin responses during an OGTT before and after a 12-week lifestyle intervention in Latino youth with obesity and impaired glucose tolerance (IGT). A total of 9 Latino youth with obesity and IGT underwent a two-hour OGTT with 30-min blood samples collected for the measurement of glucose, insulin, and incretin hormones before and after the lifestyle intervention (nutrition education and 180 min of moderate-vigorous exercise weekly for a total of 12 weeks). From pre- to post-intervention, a trend towards reduction was observed in the total GIP area under the curve (AUC) during the OGTT (5499.1 ± 715.3 vs. 4085.2 ± 389.5 pg/mL, p = 0.059), with no change in GLP-1. Moreover, BMI%, glucose AUC, and two-hour glucose concentrations were significantly reduced after the intervention. Our data suggest that a lifestyle intervention in Latino youth with obesity and IGT could influence incretin and glucose metabolism. Future studies should examine if the GIP response to a lifestyle intervention is mediated by baseline glycemic status.
胃抑制多肽（GIP）和胰高血糖素样肽-1 （GLP-1）是两种肠促胰岛素激素，在葡萄糖稳态中起重要的病理生理作用，对胰腺β细胞具有促胰岛素作用。虽然之前有两项针对年轻人的研究考察了生活方式干预对肠促胰岛素浓度的影响，但这两项研究都没有关注血糖状态的改善或口服葡萄糖耐量试验（OGTT）衍生的生物标志物。因此，我们的目的是研究肥胖和糖耐量受损（IGT）的拉丁裔青年在12周生活方式干预前后OGTT中肠促胰岛素反应的变化。共有9名患有肥胖和IGT的拉丁裔青年接受了两个小时的OGTT，并在生活方式干预（营养教育和每周180分钟的中等剧烈运动，共12周）前后采集了30分钟的血液样本，用于测量葡萄糖、胰岛素和肠促胰岛素激素。从干预前到干预后，OGTT期间总GIP曲线下面积（AUC）有降低的趋势（5499.1±715.3 vs 4085.2±389.5 pg/mL, p = 0.059）， GLP-1无变化。此外，干预后BMI%、葡萄糖AUC和两小时葡萄糖浓度显著降低。我们的数据表明，对肥胖和IGT的拉丁裔青年进行生活方式干预可能会影响肠促胰岛素和葡萄糖代谢。未来的研究应该检查GIP对生活方式干预的反应是否由基线血糖状态介导。
{"title":"The effects of a 12-week lifestyle intervention on incretin response during an oral glucose tolerance test in Latino youth with obesity and impaired glucose tolerance","authors":"Jared Rosenberg , Allison Williams , Anny Gano , Molly M. Deak , Gabriel Q. Shaibi , Joon Young Kim","doi":"10.1016/j.jdiacomp.2025.109228","DOIUrl":"10.1016/j.jdiacomp.2025.109228","url":null,"abstract":"<div><div>Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the two incretin hormones, play an important pathophysiological role in glucose homeostasis with insulinotropic effects on the pancreatic β-cells. While two previous studies in youth have examined the effects of a lifestyle intervention on incretin concentrations, neither study focused on improvements in glycemic status or oral glucose tolerance test (OGTT)-derived biomarkers. Therefore, we aimed to examine changes in the incretin responses during an OGTT before and after a 12-week lifestyle intervention in Latino youth with obesity and impaired glucose tolerance (IGT). A total of 9 Latino youth with obesity and IGT underwent a two-hour OGTT with 30-min blood samples collected for the measurement of glucose, insulin, and incretin hormones before and after the lifestyle intervention (nutrition education and 180 min of moderate-vigorous exercise weekly for a total of 12 weeks). From pre- to post-intervention, a trend towards reduction was observed in the total GIP area under the curve (AUC) during the OGTT (5499.1 ± 715.3 vs. 4085.2 ± 389.5 pg/mL, <em>p</em> = 0.059), with no change in GLP-1. Moreover, BMI%, glucose AUC, and two-hour glucose concentrations were significantly reduced after the intervention. Our data suggest that a lifestyle intervention in Latino youth with obesity and IGT could influence incretin and glucose metabolism. Future studies should examine if the GIP response to a lifestyle intervention is mediated by baseline glycemic status.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"40 1","pages":"Article 109228"},"PeriodicalIF":3.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145604447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-19DOI: 10.1016/j.jdiacomp.2025.109203
Sameer Badri Al-Mhanna , Barry A. Franklin , John M. Jakicic , Emmanuel Stamatakis , Linda S. Pescatello , Deborah Riebe , Walter R. Thompson , James S. Skinner , Sheri R. Colberg , Jonathan K. Ehrman , George S. Metsios , Norsuhana Omar , Nouf H. Alkhamees , Bodor Bin Sheeha , Abdullah F. Alghannam , Alexios Batrakoulis
Purpose
This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of aerobic exercise on cardiometabolic health-related indices in patients with type 2 diabetes and concurrent overweight/obesity (diabesity).
Methods
PubMed, Web of Science, Scopus, Science Direct, Cochrane Library, and Google Scholar databases were searched from inception to October 2024. The search strategy included the following keywords: diabetes, aerobic exercise, and endurance training. RCTs comparing aerobic exercise training ≥2 weeks in duration to standard treatment were considered eligible. Participants were adults with diabesity.
Results
A total of 1391 middle-aged/older adult patients (55 % females) were included in 34 RCTs. Body mass index [standardized mean differences (SMD) -0.18 kg/m2, 95 % confidence intervals (CI) -0.36 to −0.01]. waist circumference (SMD -0.23 cm, 95 % CI -0.44 to −0.03), body fat (SMD -0.30 %, 95 % CI -0.59 to −0.01), fasting blood glucose (SMD -0.49 mmol/L, 95 % CI -0.72 to −0.27), glycated hemoglobin (SMD -0.79 %, 95 % CI -1.17 to −0.41), fasting insulin (SMD -0.44 mIU/L, 95 % CI -0.72 to −0.15), homeostatic model assessment for insulin resistance (SMD -0.72, 95 % CI -1.09 to −0.35), high-density lipoprotein cholesterol (SMD 0.32 mg/dL, 95 % CI 0.01 to 0.63), triglycerides (SMD -0.33 mg/dL, 95 % CI -0.63 to −0.04), and total cholesterol (SMD -0.28 mg/dL, 95 % CI -0.47 to −0.10) improved compared with standard treatment.
Conclusions
These results underscore the beneficial role of aerobic exercise as a non-pharmacological intervention in managing and treating patients with diabesity when compared to standard treatment, despite the presence of considerable uncertainty in several outcomes.
目的对随机对照试验（RCTs）进行系统回顾和荟萃分析，旨在评估有氧运动对2型糖尿病合并超重/肥胖（糖尿病）患者心脏代谢相关指标的影响。方法检索spubmed、Web of Science、Scopus、Science Direct、Cochrane Library和谷歌Scholar数据库，检索时间为建库至2024年10月。搜索策略包括以下关键词：糖尿病、有氧运动和耐力训练。比较持续时间≥2周的有氧运动训练与标准治疗的rct被认为是合格的。参与者是患有糖尿病的成年人。结果34项随机对照试验共纳入1391例中老年患者，其中女性占55%。体重指数[标准化平均差(SMD) -0.18 kg/m2, 95%置信区间(CI) -0.36至- 0.01]。腰围(SMD -0.23厘米,95% CI -0.44−0.03),脂肪(SMD -0.30%, 95% CI -0.59−0.01)、空腹血糖(SMD -0.49更易/ L, 95%置信区间-0.72 - 0.27−)、糖化血红蛋白(SMD -0.79%, 95% CI -1.17−0.41)、空腹胰岛素(SMD -0.44个人/ L, 95% CI -0.72−0.15),稳态模型评估胰岛素抵抗(SMD -0.72, 95% CI -1.09−0.35),高密度脂蛋白胆固醇(SMD 0.32 mg / dL, 95%可信区间0.01到0.63),甘油三酯(SMD -0.33 mg / dL,95% CI -0.63至- 0.04)，总胆固醇（SMD -0.28 mg/dL, 95% CI -0.47至- 0.10）与标准治疗相比有所改善。结论：与标准治疗相比，这些结果强调了有氧运动作为一种非药物干预在管理和治疗糖尿病患者方面的有益作用，尽管在一些结果中存在相当大的不确定性。
{"title":"Impact of aerobic exercise on cardiometabolic health in patients with diabesity: A systematic review and meta-analysis of randomized controlled trials","authors":"Sameer Badri Al-Mhanna , Barry A. Franklin , John M. Jakicic , Emmanuel Stamatakis , Linda S. Pescatello , Deborah Riebe , Walter R. Thompson , James S. Skinner , Sheri R. Colberg , Jonathan K. Ehrman , George S. Metsios , Norsuhana Omar , Nouf H. Alkhamees , Bodor Bin Sheeha , Abdullah F. Alghannam , Alexios Batrakoulis","doi":"10.1016/j.jdiacomp.2025.109203","DOIUrl":"10.1016/j.jdiacomp.2025.109203","url":null,"abstract":"<div><h3>Purpose</h3><div>This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effects of aerobic exercise on cardiometabolic health-related indices in patients with type 2 diabetes and concurrent overweight/obesity (diabesity).</div></div><div><h3>Methods</h3><div>PubMed, Web of Science, Scopus, Science Direct, Cochrane Library, and Google Scholar databases were searched from inception to October 2024. The search strategy included the following keywords: diabetes, aerobic exercise, and endurance training. RCTs comparing aerobic exercise training ≥2 weeks in duration to standard treatment were considered eligible. Participants were adults with diabesity.</div></div><div><h3>Results</h3><div>A total of 1391 middle-aged/older adult patients (55 % females) were included in 34 RCTs. Body mass index [standardized mean differences (SMD) -0.18 kg/m<sup>2</sup>, 95 % confidence intervals (CI) -0.36 to −0.01]. waist circumference (SMD -0.23 cm, 95 % CI -0.44 to −0.03), body fat (SMD -0.30 %, 95 % CI -0.59 to −0.01), fasting blood glucose (SMD -0.49 mmol/L, 95 % CI -0.72 to −0.27), glycated hemoglobin (SMD -0.79 %, 95 % CI -1.17 to −0.41), fasting insulin (SMD -0.44 mIU/L, 95 % CI -0.72 to −0.15), homeostatic model assessment for insulin resistance (SMD -0.72, 95 % CI -1.09 to −0.35), high-density lipoprotein cholesterol (SMD 0.32 mg/dL, 95 % CI 0.01 to 0.63), triglycerides (SMD -0.33 mg/dL, 95 % CI -0.63 to −0.04), and total cholesterol (SMD -0.28 mg/dL, 95 % CI -0.47 to −0.10) improved compared with standard treatment.</div></div><div><h3>Conclusions</h3><div>These results underscore the beneficial role of aerobic exercise as a non-pharmacological intervention in managing and treating patients with diabesity when compared to standard treatment, despite the presence of considerable uncertainty in several outcomes.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109203"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145359892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-15DOI: 10.1016/j.jdiacomp.2025.109196
Hulya Yilmaz Aydogan , Deniz Kanca Demirci , Nurdan Gul , Fatih Yanar , Sukran Poyrazoglu , Seda Gulec Yilmaz , Mete Bora Tuzuner , Turgay Isbir , Oguz Ozturk , Ilhan Satman
Background
The distribution of intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions specific to diabetes types and changes under dyslipidemia conditions have been well characterised. Research into the distribution of lipoprotein subfractions in Maturity-Onset Diabetes of the Young (MODY) has hitherto been confined to certain subtypes, with gender-based differences remaining to be elucidated. The objective of this study was to comparatively evaluate the distribution of lipoprotein subfractions according to gender in MODY, T2DM patients, and control groups.
Methods
Lipoprotein subfractions in 119 serum samples of the study groups were analyzed using the Lipoprint-System.
Results
The midbands of IDL (MID-A to C) in female MODY cases, and the HDL-small fraction in male MODY cases, were found to be lower compared to female and male T2DM cases, respectively. In the T2DM group, age was positively correlated with MID-C and MID-B in both genders, while it was negatively correlated with MID-A in female cases. ROC analysis demonstrated that the decrease in the MID-C fraction in female MODY subjects (AUC:0.809, p = 0.0001) and the decrease in the HDL-small fraction in male MODY subjects (AUC:0.818, p = 0.002) were significantly associated with the likelihood of MODY.
Conclusion
Given that a considerable proportion of MODY patients are frequently misdiagnosed as T2DM, low levels of MID-C and HDL-small fractions, both of which are triglyceride-rich, may have potential as a diagnostic value for female and male MODY patients, respectively.
背景：中密度脂蛋白（IDL）、低密度脂蛋白（LDL）和高密度脂蛋白（HDL）亚组分的分布已经很好地表征了糖尿病类型和血脂异常条件下的变化。迄今为止，对成熟型糖尿病（MODY）中脂蛋白亚组分分布的研究仅限于某些亚型，性别差异仍有待阐明。本研究的目的是比较评价MODY、T2DM和对照组中不同性别的脂蛋白亚组分分布。方法采用脂印系统对119份研究组血清中的脂蛋白亚组分进行分析。结果女性MODY患者的IDL中带（MID-A ~ C）和男性MODY患者的HDL-small比例分别低于女性和男性T2DM患者。在T2DM组中，年龄与男女MID-C、MID-B呈正相关，与女性MID-A呈负相关。ROC分析显示，女性MODY受试者中MID-C分数的降低（AUC:0.809, p = 0.0001）和男性MODY受试者中hdl -小分数的降低（AUC:0.818, p = 0.002）与MODY发生的可能性显著相关。鉴于相当比例的MODY患者经常被误诊为T2DM，低水平的中c和高密度脂蛋白小分数（两者都富含甘油三酯）可能分别对女性和男性MODY患者具有潜在的诊断价值。
{"title":"Gender differences in the distribution of IDL, LDL, and HDL lipoprotein subfractions in MODY compared to type 2 diabetes: Data from the MODY-Ist study","authors":"Hulya Yilmaz Aydogan , Deniz Kanca Demirci , Nurdan Gul , Fatih Yanar , Sukran Poyrazoglu , Seda Gulec Yilmaz , Mete Bora Tuzuner , Turgay Isbir , Oguz Ozturk , Ilhan Satman","doi":"10.1016/j.jdiacomp.2025.109196","DOIUrl":"10.1016/j.jdiacomp.2025.109196","url":null,"abstract":"<div><h3>Background</h3><div>The distribution of intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions specific to diabetes types and changes under dyslipidemia conditions have been well characterised. Research into the distribution of lipoprotein subfractions in Maturity-Onset Diabetes of the Young (MODY) has hitherto been confined to certain subtypes, with gender-based differences remaining to be elucidated. The objective of this study was to comparatively evaluate the distribution of lipoprotein subfractions according to gender in MODY, T2DM patients, and control groups.</div></div><div><h3>Methods</h3><div>Lipoprotein subfractions in 119 serum samples of the study groups were analyzed using the Lipoprint-System.</div></div><div><h3>Results</h3><div>The midbands of IDL (MID-A to C) in female MODY cases, and the HDL-small fraction in male MODY cases, were found to be lower compared to female and male T2DM cases, respectively. In the T2DM group, age was positively correlated with MID-C and MID-B in both genders, while it was negatively correlated with MID-A in female cases. ROC analysis demonstrated that the decrease in the MID-C fraction in female MODY subjects (AUC:0.809, <em>p</em> = 0.0001) and the decrease in the HDL-small fraction in male MODY subjects (AUC:0.818, <em>p</em> = 0.002) were significantly associated with the likelihood of MODY.</div></div><div><h3>Conclusion</h3><div>Given that a considerable proportion of MODY patients are frequently misdiagnosed as T2DM, low levels of MID-C and HDL-small fractions, both of which are triglyceride-rich, may have potential as a diagnostic value for female and male MODY patients, respectively.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109196"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-10-21DOI: 10.1016/j.jdiacomp.2025.109205
Fulden Sari , Zilan Bazancir-Apaydın , Süleyman Sari , Mehmet Can Sari , Şenol Çelik
Aim
Swallowing difficulties are increasingly recognized as a significant yet underreported complication of diabetes mellitus (DM), with evidence suggesting that more than 50 % of patients with the condition may be affected. This study aimed to assess the impact of swallowing disorders on the quality of life in DM patients, to identify other factors influencing swallowing disorders, and to determine the cut-off score for the SWAL-QOL questionnaire in these patients using data mining methods.
Methods
This cross-sectional study analyzed 150 DM patients, assessing swallowing assessment using the EAT-10, quality of life with the SWAL-QOL, and swallowing difficulty through the Visual Analogue Scale (VAS).
Results
Patients with dysphagia exhibited significantly lower scores across multiple SWAL-QOL subgroups-including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total SWAL-QOL score compared to non-dysphagic patients (p < 0.001). The Swallowing Difficulty-VAS score was significantly elevated in dysphagic patients (p < 0.001). EAT-10 scores were correlated with Swallowing Difficulty-VAS and SWAL-QOL subgroups, including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total score. The SWAL-QOL total score cut-off of 65.7 was identified for DM patients with dysphagia.
Conclusions
Close monitoring of these symptoms by clinicians is essential, and targeted rehabilitation interventions are strongly recommended to improve both swallowing function and overall quality of life in this population.
{"title":"Assessing the impact of dysphagia on quality of life and determining SWAL-QOL cut-off scores in diabetes mellitus patients: a data mining approach","authors":"Fulden Sari , Zilan Bazancir-Apaydın , Süleyman Sari , Mehmet Can Sari , Şenol Çelik","doi":"10.1016/j.jdiacomp.2025.109205","DOIUrl":"10.1016/j.jdiacomp.2025.109205","url":null,"abstract":"<div><h3>Aim</h3><div>Swallowing difficulties are increasingly recognized as a significant yet underreported complication of diabetes mellitus (DM), with evidence suggesting that more than 50 % of patients with the condition may be affected. This study aimed to assess the impact of swallowing disorders on the quality of life in DM patients, to identify other factors influencing swallowing disorders, and to determine the cut-off score for the SWAL-QOL questionnaire in these patients using data mining methods.</div></div><div><h3>Methods</h3><div>This cross-sectional study analyzed 150 DM patients, assessing swallowing assessment using the EAT-10, quality of life with the SWAL-QOL, and swallowing difficulty through the Visual Analogue Scale (VAS).</div></div><div><h3>Results</h3><div>Patients with dysphagia exhibited significantly lower scores across multiple SWAL-QOL subgroups-including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total SWAL-QOL score compared to non-dysphagic patients (p < 0.001). The Swallowing Difficulty-VAS score was significantly elevated in dysphagic patients (p < 0.001). EAT-10 scores were correlated with Swallowing Difficulty-VAS and SWAL-QOL subgroups, including General Burden, Food Selection, Eating Duration, Eating Desire, Fear of Eating, Sleep, Fatigue, Communication, Mental Health, Social Functioning, and the total score. The SWAL-QOL total score cut-off of 65.7 was identified for DM patients with dysphagia.</div></div><div><h3>Conclusions</h3><div>Close monitoring of these symptoms by clinicians is essential, and targeted rehabilitation interventions are strongly recommended to improve both swallowing function and overall quality of life in this population.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109205"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145359893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.
Methods
In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.
Results
Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.
Conclusion
Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.
{"title":"Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study","authors":"Nikolaos Angelopoulos , Sarantis Livadas , Ioannis Androulakis , Valentina Petkova , Andreas Rizoulis , Anastasios Boniakos , Rodis Paparodis , Ploutarchos Tzoulis , Voula Mentzelopoulou , Dimos Florakis , Evangelos Fousteris , Areti Korakovouni , Dimitra Zianni , Zadalla Mouslech , Manfredi Rizzo , Dimitri P. Mikhailidis , Panagiotis Anagnostis","doi":"10.1016/j.jdiacomp.2025.109181","DOIUrl":"10.1016/j.jdiacomp.2025.109181","url":null,"abstract":"<div><h3>Background/aims</h3><div>Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.</div></div><div><h3>Methods</h3><div>In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.</div></div><div><h3>Results</h3><div>Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.</div></div><div><h3>Conclusion</h3><div>Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109181"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145247846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号